{"id":343830,"date":"2025-08-24T06:27:16","date_gmt":"2025-08-24T06:27:16","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-apellis-pharmaceuticals\/"},"modified":"2025-08-24T06:27:16","modified_gmt":"2025-08-24T06:27:16","slug":"how-to-buy-apellis-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/","title":{"rendered":"Apellis Pharmaceuticals, Inc. (APLS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Apellis Pharmaceuticals, Inc. (APLS) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334081,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-343830","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Apellis Pharmaceuticals, Inc. (APLS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Apellis Pharmaceuticals, Inc. (APLS) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Apellis Pharmaceuticals, Inc. (APLS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Apellis Pharmaceuticals, Inc. (APLS) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Apellis Pharmaceuticals (APLS) hisselerini g\u00fcncel fiyat\u0131 $27,97 ile nas\u0131l alaca\u011f\u0131n\u0131z\u0131 \u00f6\u011frenin. Bu biyoteknoloji lideri i\u00e7in yat\u0131r\u0131m stratejilerini, riskleri ve b\u00fcy\u00fcme potansiyelini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Apellis Pharmaceuticals (APLS) hisselerini g\u00fcncel fiyat\u0131 $27,97 ile nas\u0131l alaca\u011f\u0131n\u0131z\u0131 \u00f6\u011frenin. Bu biyoteknoloji lideri i\u00e7in yat\u0131r\u0131m stratejilerini, riskleri ve b\u00fcy\u00fcme potansiyelini ke\u015ffedin."},"intro":"G\u00f6z hastal\u0131klar\u0131 tedavisinde devrim yaratan bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Apellis Pharmaceuticals, t\u0131bbi yenilik ve yat\u0131r\u0131m f\u0131rsat\u0131n\u0131n heyecan verici kesi\u015fimini temsil ediyor. Co\u011frafi atrofi i\u00e7in \u00e7\u0131\u011f\u0131r a\u00e7an SYFOVRE tedavisi ve yak\u0131n zamanda al\u0131nan FDA onaylar\u0131 ile bu biyoteknoloji firmas\u0131 hem bilimsel vaat hem de finansal potansiyel sunuyor. APLS hissesini neden dikkate alman\u0131z gerekti\u011fini birlikte ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"G\u00f6z hastal\u0131klar\u0131 tedavisinde devrim yaratan bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Apellis Pharmaceuticals, t\u0131bbi yenilik ve yat\u0131r\u0131m f\u0131rsat\u0131n\u0131n heyecan verici kesi\u015fimini temsil ediyor. Co\u011frafi atrofi i\u00e7in \u00e7\u0131\u011f\u0131r a\u00e7an SYFOVRE tedavisi ve yak\u0131n zamanda al\u0131nan FDA onaylar\u0131 ile bu biyoteknoloji firmas\u0131 hem bilimsel vaat hem de finansal potansiyel sunuyor. APLS hissesini neden dikkate alman\u0131z gerekti\u011fini birlikte ke\u015ffedelim."},"body_html":"<h2>Mevcut Piyasa Konumu ve Giri\u015f Noktas\u0131<\/h2> <p>24 A\u011fustos 2025 itibar\u0131yla Apellis Pharmaceuticals (APLS) hisseleri <strong>27,97 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, Apellis Pharmaceuticals, Inc. (APLS) hisselerini nas\u0131l alaca\u011f\u0131n\u0131 d\u00fc\u015f\u00fcnen yat\u0131r\u0131mc\u0131lar i\u00e7in kritik bir d\u00f6n\u00fcm noktas\u0131d\u0131r; \u00e7\u00fcnk\u00fc hisse senedi son aylarda kayda de\u011fer bir toparlanma ivmesi g\u00f6stermi\u015ftir.<\/p> <p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131<\/strong>: Takviminize <strong>4 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin. Bu tarihte Apellis \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayacak. Tarihsel veriler, bu t\u00fcr olaylar\u0131n APLS hisse fiyat\u0131 hareketleri \u00fczerinde \u00f6nemli etkileri oldu\u011funu g\u00f6stermektedir.<\/p> <p><strong>Kazan\u00e7 Etkisi Analizi<\/strong>:<br\/> Son \u00e7eyrek raporlar\u0131na bak\u0131ld\u0131\u011f\u0131nda, Apellis hisseleri genellikle kazan\u00e7 a\u00e7\u0131klamalar\u0131 etraf\u0131nda %5-15 aras\u0131nda fiyat dalgalanmalar\u0131 ya\u015famaktad\u0131r. 31 Temmuz'daki 2025 ikinci \u00e7eyrek raporu kar\u0131\u015f\u0131k sonu\u00e7lar g\u00f6sterdi - gelir beklentileri kar\u015f\u0131lamad\u0131 ancak hisse ba\u015f\u0131na kazan\u00e7 tahminlerin %25 \u00fczerinde ger\u00e7ekle\u015fti. Bu durum, Apellis Pharmaceuticals, Inc. (APLS) hissesine yat\u0131r\u0131m yaparken hem \u00fcst \u00e7izgi hem de alt \u00e7izgi performans\u0131n\u0131n dikkatle analiz edilmesi gerekti\u011fini g\u00f6stermektedir.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>Alt\u0131 Ayl\u0131k Fiyat Yolculu\u011fu: M\u00fccadeleden G\u00fcce<\/h2> <p>Apellis hisseleri son alt\u0131 ayda dramatik bir d\u00f6n\u00fc\u015f\u00fcm ya\u015fad\u0131:<\/p> <ul> <li><strong>Ocak 2025<\/strong>: Yakla\u015f\u0131k 35,57 $ ile ba\u015flad\u0131, ard\u0131ndan endi\u015fe verici bir d\u00fc\u015f\u00fc\u015f ba\u015flad\u0131<\/li> <li><strong>\u015eubat-Mart<\/strong>: D\u00fc\u015f\u00fc\u015f devam etti, 26-30 $ aral\u0131\u011f\u0131na geriledi<\/li> <li><strong>Nisan-May\u0131s<\/strong>: 16-17 $ civar\u0131nda endi\u015fe verici dipler g\u00f6r\u00fcld\u00fc, yat\u0131r\u0131mc\u0131 sabr\u0131 test edildi<\/li> <li><strong>Haziran-Temmuz<\/strong>: S\u0131ras\u0131yla %2,24 ve %12,48 ayl\u0131k kazan\u00e7larla dikkat \u00e7ekici bir toparlanma<\/li> <li><strong>A\u011fustos 2025<\/strong>: Toparlanma devam etti, mevcut seviyeler olan yakla\u015f\u0131k 28 $ civar\u0131na ula\u015ft\u0131<\/li> <\/ul> <p>Bu, klasik bir biyoteknoloji volatilite modelini temsil ediyor - keskin d\u00fc\u015f\u00fc\u015fler ard\u0131ndan patlay\u0131c\u0131 toparlanmalar. Apellis Pharmaceuticals, Inc. (APLS) hisselerini nas\u0131l alaca\u011f\u0131n\u0131z\u0131 \u00f6\u011frenenler i\u00e7in bu tarih\u00e7e, ila\u00e7 yat\u0131r\u0131mlar\u0131ndaki riskleri ve f\u0131rsatlar\u0131 g\u00f6stermektedir.<\/p> <h2>Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve \u015firket geli\u015fmelerine dayanarak, beklenenler \u015funlard\u0131r:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu<\/strong>: 30-34 $ aral\u0131\u011f\u0131 (mevcut seviyelerden \u0131l\u0131ml\u0131 b\u00fcy\u00fcme)<\/li> <li><strong>2026 Projeksiyonu<\/strong>: 28-32 $ (konsolidasyon d\u00f6nemi bekleniyor)<\/li> <li><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 48-52 $ (pipeline geni\u015flemesinden \u00f6nemli b\u00fcy\u00fcme potansiyeli)<\/li> <li><strong>2030 Vizyonu<\/strong>: 50-55+ $ (piyasa liderli\u011finden uzun vadeli de\u011fer yarat\u0131m\u0131)<\/li> <\/ul> <p><strong>Karar<\/strong>: Uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in <strong>AL<\/strong>. EMPAVELI i\u00e7in yak\u0131n zamanda al\u0131nan FDA onay\u0131 ve g\u00fc\u00e7l\u00fc SYFOVRE performans\u0131, gelecekteki b\u00fcy\u00fcmeyi destekleyen temel g\u00fc\u00e7lerdir.<\/p> <h2>Risk De\u011ferlendirmesi ve Pozitif Sinyaller<\/h2> <h3>\u26a0\ufe0f Dikkate Al\u0131nmas\u0131 Gereken Temel Riskler:<\/h3> <ul> <li><strong>Reg\u00fclasyon belirsizli\u011fi<\/strong>: FDA kararlar\u0131 biyoteknoloji hisselerini olumlu ya da olumsuz etkileyebilir<\/li> <li><strong>Artan rekabet<\/strong>: Benzer tedaviler geli\u015ftiren di\u011fer \u015firketler<\/li> <li><strong>Nakit t\u00fcketimi endi\u015feleri<\/strong>: 370 milyon $ nakit pozisyonuna ra\u011fmen, Ar-Ge maliyetleri y\u00fcksek kal\u0131yor<\/li> <li><strong>Piyasa volatilitesi<\/strong>: Biyoteknoloji hisseleri genellikle piyasa ortalamas\u0131ndan daha y\u00fcksek beta g\u00f6sterir<\/li> <\/ul> <h3>\u2705 2025 \u0130\u00e7in Pozitif Sinyaller:<\/h3> <ul> <li><strong>FDA onay ba\u015far\u0131s\u0131<\/strong>: EMPAVELI, C3G\/IC-MPGN i\u00e7in onay ald\u0131 (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/07\/31\/3124861\/0\/en\/Apellis-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results.html\">2. \u00c7eyrek Kazan\u00e7 Raporu<\/a>)<\/li> <li><strong>Gelir art\u0131\u015f\u0131<\/strong>: SYFOVRE, 2. \u00e7eyrekte 151 milyon $ gelir elde etti, \u00e7eyreklik %6 art\u0131\u015f<\/li> <li><strong>Stratejik ortakl\u0131klar<\/strong>: Sobi ile 300 milyon $ lisans anla\u015fmas\u0131 finansal istikrar sa\u011fl\u0131yor<\/li> <li><strong>Piyasa liderli\u011fi<\/strong>: SYFOVRE, co\u011frafi atrofi hastalar\u0131nda %60'tan fazla yeni hasta pay\u0131 yakalad\u0131<\/li> <\/ul> <h2>Son Haberlerin Etki Analizi<\/h2> <p>Apellis, 2025 y\u0131l\u0131nda birka\u00e7 \u00f6nemli geli\u015fmeyle g\u00fcndemde:<\/p> <ul> <li><strong>2. \u00c7eyrek Kazan\u00e7 Performans\u0131<\/strong>: 178 milyon $ gelir beklentileri kar\u015f\u0131lamasa da, hisse ba\u015f\u0131na kazan\u00e7 %25 \u00fczerinde ger\u00e7ekle\u015ferek operasyonel verimlili\u011fin artt\u0131\u011f\u0131n\u0131 g\u00f6steriyor (<a href=\"https:\/\/www.ainvest.com\/news\/apellis-pharmaceuticals-reports-q2-revenue-expectations-celebrates-fda-approval-empaveli-2508\/\">AInvest Analizi<\/a>)<\/li> <li><strong>FDA Geni\u015flemesi<\/strong>: EMPAVELI'nin ek durumlar i\u00e7in onay\u0131, hasta ba\u015f\u0131na potansiyel 500 milyon $ pazar f\u0131rsat\u0131 a\u00e7\u0131yor (<a href=\"https:\/\/www.ainvest.com\/news\/apellis-pharmaceuticals-q2-2025-unraveling-contradictions-sales-dynamics-market-position-competitive-landscape-2508\/\">Piyasa Analizi<\/a>)<\/li> <li><strong>Kurumsal G\u00fcven<\/strong>: Fox Run Management'\u0131n A\u011fustos 2025'teki yeni yat\u0131r\u0131m\u0131 profesyonel ilginin devam etti\u011fini g\u00f6steriyor (<a href=\"https:\/\/www.marketbeat.com\/instant-alerts\/filing-fox-run-management-llc-makes-new-investment-in-apellis-pharmaceuticals-inc-apls-2025-08-20\/\">Kurumsal Dosyalama<\/a>)<\/li> <\/ul> <h2>Ad\u0131m Ad\u0131m: Apellis Pharmaceuticals, Inc. (APLS) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir i\u015flem platformu se\u00e7in<\/td><td>ABD hisseleri i\u00e7in NASDAQ eri\u015fimi sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td><td>\u00c7o\u011fu platform kimlik ve adres do\u011frulamas\u0131 ister<\/td><\/tr> <tr><td>3<\/td><td>Fon yat\u0131r\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Mevcut APLS fiyat\u0131n\u0131 ara\u015ft\u0131r\u0131n<\/td><td>Sipari\u015f vermeden \u00f6nce ger\u00e7ek zamanl\u0131 fiyatlar\u0131 kontrol edin<\/td><\/tr> <tr><td>5<\/td><td>Sipari\u015finizi verin<\/td><td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>6<\/td><td>Yat\u0131r\u0131m\u0131n\u0131z\u0131 izleyin<\/td><td>\u00d6nemli seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 ayarlay\u0131n<\/td><\/tr> <tr><td>7<\/td><td>Dolar-maliyet ortalamas\u0131n\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/td><td>Zamanlama riskini azaltmak i\u00e7in al\u0131mlar\u0131 zamana yaymak<\/td><\/tr> <\/tbody> <\/table> <h2>Yeni Ba\u015flayanlar \u0130\u00e7in Ak\u0131ll\u0131 Strateji<\/h2> <p>Apellis Pharmaceuticals, Inc. (APLS) hisselerini nas\u0131l alaca\u011f\u0131n\u0131z\u0131 \u00f6\u011frenenler i\u00e7in profesyonel tavsiyem:<\/p> <ul> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> - Biyoteknoloji hisseleri volatil olabilir; sizi uyutmayan bir pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ile ba\u015flay\u0131n<\/li> <li><strong>Uzun vadeye odaklan\u0131n<\/strong> - \u0130la\u00e7 geli\u015ftirme y\u0131llar al\u0131r; 3-5 y\u0131ll\u0131k perspektifle d\u00fc\u015f\u00fcn\u00fcn<\/li> <li><strong>Uygun \u015fekilde \u00e7e\u015fitlendirin<\/strong> - T\u00fcm yat\u0131r\u0131mlar\u0131n\u0131z\u0131 tek bir biyoteknoloji sepetine koymay\u0131n<\/li> <li><strong>Stop-loss emirleri belirleyin<\/strong> - Beklenmedik d\u00fc\u015f\u00fc\u015flere kar\u015f\u0131 sermayenizi koruyun<\/li> <\/ul> <p>Ve mizahi yorumum: \"APLS ticareti, t\u0131bbi ara\u015ft\u0131rmalar\u0131 izlemek gibidir - bazen klinik deneyler i\u00e7in g\u00fc\u00e7l\u00fc bir mide gerekir, ama ba\u015far\u0131l\u0131 tedaviler beklemeye de\u011fer k\u0131lar!\"<\/p> <h2>Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option'\u0131n Avantajlar\u0131<\/h2> <p>Apellis Pharmaceuticals, Inc. (APLS) hisselerini nas\u0131l alaca\u011f\u0131n\u0131z\u0131 d\u00fc\u015f\u00fcnenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum depozito sadece 5 $<\/strong> - Stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> - Basit belge y\u00fckleme ile h\u0131zl\u0131ca i\u015flem yapmaya ba\u015flay\u0131n<\/li> <li><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong> - Karlar\u0131n\u0131za \u00e7e\u015fitli kolay y\u00f6ntemlerle eri\u015fin<\/li> <li><strong>Kullan\u0131c\u0131 dostu platform<\/strong> - Yeni ba\u015flayanlar i\u00e7in tasarlanm\u0131\u015f, geli\u015fmi\u015f \u00f6zellikler sunar<\/li> <\/ul> <h2>\u015eirket Genel Bak\u0131\u015f\u0131: 2025'te Apellis<\/h2> <p>Apellis Pharmaceuticals, tamamlay\u0131c\u0131 arac\u0131l\u0131 hastal\u0131k tedavisinde k\u00fcresel lider konumundad\u0131r. \u015eirket, klinik a\u015famadan ticari a\u015famaya ge\u00e7i\u015f yapm\u0131\u015f ve ciddi hastal\u0131klar\u0131 hedefleyen iki onayl\u0131 terapiye sahiptir.<\/p> <p>Amiral gemisi \u00fcr\u00fcn\u00fc SYFOVRE co\u011frafi atrofiyi tedavi ederken, EMPAVELI birden fazla nadir hastal\u0131\u011f\u0131 hedeflemektedir. 370 milyon $ nakit ve artan gelir ak\u0131\u015flar\u0131 ile Apellis hem bilimsel yenilik hem de i\u015f zekas\u0131 sergilemektedir.<\/p> <p><strong>\u0130lgin\u00e7 Ger\u00e7ek<\/strong>: 2025 y\u0131l\u0131nda Apellis biyoteknolojide nadir g\u00f6r\u00fclen bir ba\u015far\u0131ya imza att\u0131 - mevcut ilac\u0131 EMPAVELI'yi tamamen yeni durumlar\u0131 (C3G ve IC-MPGN) tedavi etmek i\u00e7in geni\u015fletti, b\u00f6ylece tamamen yeni bile\u015fikler geli\u015ftirmeden yeni gelir ak\u0131\u015flar\u0131 yaratt\u0131!<\/p> <p>Yat\u0131r\u0131m stratejileri ve piyasa analizleri hakk\u0131nda daha fazla e\u011fitim i\u00e7eri\u011fi i\u00e7in d\u00fczenli g\u00fcncellemeler ve i\u00e7g\u00f6r\u00fcler sunan <a href=\"\/blog\">Pocket Option blog<\/a> sayfam\u0131z\u0131 ziyaret edin.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>Mevcut Piyasa Konumu ve Giri\u015f Noktas\u0131<\/h2>\n<p>24 A\u011fustos 2025 itibar\u0131yla Apellis Pharmaceuticals (APLS) hisseleri <strong>27,97 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, Apellis Pharmaceuticals, Inc. (APLS) hisselerini nas\u0131l alaca\u011f\u0131n\u0131 d\u00fc\u015f\u00fcnen yat\u0131r\u0131mc\u0131lar i\u00e7in kritik bir d\u00f6n\u00fcm noktas\u0131d\u0131r; \u00e7\u00fcnk\u00fc hisse senedi son aylarda kayda de\u011fer bir toparlanma ivmesi g\u00f6stermi\u015ftir.<\/p>\n<p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131<\/strong>: Takviminize <strong>4 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin. Bu tarihte Apellis \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayacak. Tarihsel veriler, bu t\u00fcr olaylar\u0131n APLS hisse fiyat\u0131 hareketleri \u00fczerinde \u00f6nemli etkileri oldu\u011funu g\u00f6stermektedir.<\/p>\n<p><strong>Kazan\u00e7 Etkisi Analizi<\/strong>:<br \/> Son \u00e7eyrek raporlar\u0131na bak\u0131ld\u0131\u011f\u0131nda, Apellis hisseleri genellikle kazan\u00e7 a\u00e7\u0131klamalar\u0131 etraf\u0131nda %5-15 aras\u0131nda fiyat dalgalanmalar\u0131 ya\u015famaktad\u0131r. 31 Temmuz&#8217;daki 2025 ikinci \u00e7eyrek raporu kar\u0131\u015f\u0131k sonu\u00e7lar g\u00f6sterdi &#8211; gelir beklentileri kar\u015f\u0131lamad\u0131 ancak hisse ba\u015f\u0131na kazan\u00e7 tahminlerin %25 \u00fczerinde ger\u00e7ekle\u015fti. Bu durum, Apellis Pharmaceuticals, Inc. (APLS) hissesine yat\u0131r\u0131m yaparken hem \u00fcst \u00e7izgi hem de alt \u00e7izgi performans\u0131n\u0131n dikkatle analiz edilmesi gerekti\u011fini g\u00f6stermektedir.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>Alt\u0131 Ayl\u0131k Fiyat Yolculu\u011fu: M\u00fccadeleden G\u00fcce<\/h2>\n<p>Apellis hisseleri son alt\u0131 ayda dramatik bir d\u00f6n\u00fc\u015f\u00fcm ya\u015fad\u0131:<\/p>\n<ul>\n<li><strong>Ocak 2025<\/strong>: Yakla\u015f\u0131k 35,57 $ ile ba\u015flad\u0131, ard\u0131ndan endi\u015fe verici bir d\u00fc\u015f\u00fc\u015f ba\u015flad\u0131<\/li>\n<li><strong>\u015eubat-Mart<\/strong>: D\u00fc\u015f\u00fc\u015f devam etti, 26-30 $ aral\u0131\u011f\u0131na geriledi<\/li>\n<li><strong>Nisan-May\u0131s<\/strong>: 16-17 $ civar\u0131nda endi\u015fe verici dipler g\u00f6r\u00fcld\u00fc, yat\u0131r\u0131mc\u0131 sabr\u0131 test edildi<\/li>\n<li><strong>Haziran-Temmuz<\/strong>: S\u0131ras\u0131yla %2,24 ve %12,48 ayl\u0131k kazan\u00e7larla dikkat \u00e7ekici bir toparlanma<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: Toparlanma devam etti, mevcut seviyeler olan yakla\u015f\u0131k 28 $ civar\u0131na ula\u015ft\u0131<\/li>\n<\/ul>\n<p>Bu, klasik bir biyoteknoloji volatilite modelini temsil ediyor &#8211; keskin d\u00fc\u015f\u00fc\u015fler ard\u0131ndan patlay\u0131c\u0131 toparlanmalar. Apellis Pharmaceuticals, Inc. (APLS) hisselerini nas\u0131l alaca\u011f\u0131n\u0131z\u0131 \u00f6\u011frenenler i\u00e7in bu tarih\u00e7e, ila\u00e7 yat\u0131r\u0131mlar\u0131ndaki riskleri ve f\u0131rsatlar\u0131 g\u00f6stermektedir.<\/p>\n<h2>Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve \u015firket geli\u015fmelerine dayanarak, beklenenler \u015funlard\u0131r:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu<\/strong>: 30-34 $ aral\u0131\u011f\u0131 (mevcut seviyelerden \u0131l\u0131ml\u0131 b\u00fcy\u00fcme)<\/li>\n<li><strong>2026 Projeksiyonu<\/strong>: 28-32 $ (konsolidasyon d\u00f6nemi bekleniyor)<\/li>\n<li><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 48-52 $ (pipeline geni\u015flemesinden \u00f6nemli b\u00fcy\u00fcme potansiyeli)<\/li>\n<li><strong>2030 Vizyonu<\/strong>: 50-55+ $ (piyasa liderli\u011finden uzun vadeli de\u011fer yarat\u0131m\u0131)<\/li>\n<\/ul>\n<p><strong>Karar<\/strong>: Uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in <strong>AL<\/strong>. EMPAVELI i\u00e7in yak\u0131n zamanda al\u0131nan FDA onay\u0131 ve g\u00fc\u00e7l\u00fc SYFOVRE performans\u0131, gelecekteki b\u00fcy\u00fcmeyi destekleyen temel g\u00fc\u00e7lerdir.<\/p>\n<h2>Risk De\u011ferlendirmesi ve Pozitif Sinyaller<\/h2>\n<h3>\u26a0\ufe0f Dikkate Al\u0131nmas\u0131 Gereken Temel Riskler:<\/h3>\n<ul>\n<li><strong>Reg\u00fclasyon belirsizli\u011fi<\/strong>: FDA kararlar\u0131 biyoteknoloji hisselerini olumlu ya da olumsuz etkileyebilir<\/li>\n<li><strong>Artan rekabet<\/strong>: Benzer tedaviler geli\u015ftiren di\u011fer \u015firketler<\/li>\n<li><strong>Nakit t\u00fcketimi endi\u015feleri<\/strong>: 370 milyon $ nakit pozisyonuna ra\u011fmen, Ar-Ge maliyetleri y\u00fcksek kal\u0131yor<\/li>\n<li><strong>Piyasa volatilitesi<\/strong>: Biyoteknoloji hisseleri genellikle piyasa ortalamas\u0131ndan daha y\u00fcksek beta g\u00f6sterir<\/li>\n<\/ul>\n<h3>\u2705 2025 \u0130\u00e7in Pozitif Sinyaller:<\/h3>\n<ul>\n<li><strong>FDA onay ba\u015far\u0131s\u0131<\/strong>: EMPAVELI, C3G\/IC-MPGN i\u00e7in onay ald\u0131 (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/07\/31\/3124861\/0\/en\/Apellis-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results.html\">2. \u00c7eyrek Kazan\u00e7 Raporu<\/a>)<\/li>\n<li><strong>Gelir art\u0131\u015f\u0131<\/strong>: SYFOVRE, 2. \u00e7eyrekte 151 milyon $ gelir elde etti, \u00e7eyreklik %6 art\u0131\u015f<\/li>\n<li><strong>Stratejik ortakl\u0131klar<\/strong>: Sobi ile 300 milyon $ lisans anla\u015fmas\u0131 finansal istikrar sa\u011fl\u0131yor<\/li>\n<li><strong>Piyasa liderli\u011fi<\/strong>: SYFOVRE, co\u011frafi atrofi hastalar\u0131nda %60&#8217;tan fazla yeni hasta pay\u0131 yakalad\u0131<\/li>\n<\/ul>\n<h2>Son Haberlerin Etki Analizi<\/h2>\n<p>Apellis, 2025 y\u0131l\u0131nda birka\u00e7 \u00f6nemli geli\u015fmeyle g\u00fcndemde:<\/p>\n<ul>\n<li><strong>2. \u00c7eyrek Kazan\u00e7 Performans\u0131<\/strong>: 178 milyon $ gelir beklentileri kar\u015f\u0131lamasa da, hisse ba\u015f\u0131na kazan\u00e7 %25 \u00fczerinde ger\u00e7ekle\u015ferek operasyonel verimlili\u011fin artt\u0131\u011f\u0131n\u0131 g\u00f6steriyor (<a href=\"https:\/\/www.ainvest.com\/news\/apellis-pharmaceuticals-reports-q2-revenue-expectations-celebrates-fda-approval-empaveli-2508\/\">AInvest Analizi<\/a>)<\/li>\n<li><strong>FDA Geni\u015flemesi<\/strong>: EMPAVELI&#8217;nin ek durumlar i\u00e7in onay\u0131, hasta ba\u015f\u0131na potansiyel 500 milyon $ pazar f\u0131rsat\u0131 a\u00e7\u0131yor (<a href=\"https:\/\/www.ainvest.com\/news\/apellis-pharmaceuticals-q2-2025-unraveling-contradictions-sales-dynamics-market-position-competitive-landscape-2508\/\">Piyasa Analizi<\/a>)<\/li>\n<li><strong>Kurumsal G\u00fcven<\/strong>: Fox Run Management&#8217;\u0131n A\u011fustos 2025&#8217;teki yeni yat\u0131r\u0131m\u0131 profesyonel ilginin devam etti\u011fini g\u00f6steriyor (<a href=\"https:\/\/www.marketbeat.com\/instant-alerts\/filing-fox-run-management-llc-makes-new-investment-in-apellis-pharmaceuticals-inc-apls-2025-08-20\/\">Kurumsal Dosyalama<\/a>)<\/li>\n<\/ul>\n<h2>Ad\u0131m Ad\u0131m: Apellis Pharmaceuticals, Inc. (APLS) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir i\u015flem platformu se\u00e7in<\/td>\n<td>ABD hisseleri i\u00e7in NASDAQ eri\u015fimi sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>\u00c7o\u011fu platform kimlik ve adres do\u011frulamas\u0131 ister<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fon yat\u0131r\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Mevcut APLS fiyat\u0131n\u0131 ara\u015ft\u0131r\u0131n<\/td>\n<td>Sipari\u015f vermeden \u00f6nce ger\u00e7ek zamanl\u0131 fiyatlar\u0131 kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Sipari\u015finizi verin<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Yat\u0131r\u0131m\u0131n\u0131z\u0131 izleyin<\/td>\n<td>\u00d6nemli seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 ayarlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Dolar-maliyet ortalamas\u0131n\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/td>\n<td>Zamanlama riskini azaltmak i\u00e7in al\u0131mlar\u0131 zamana yaymak<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Yeni Ba\u015flayanlar \u0130\u00e7in Ak\u0131ll\u0131 Strateji<\/h2>\n<p>Apellis Pharmaceuticals, Inc. (APLS) hisselerini nas\u0131l alaca\u011f\u0131n\u0131z\u0131 \u00f6\u011frenenler i\u00e7in profesyonel tavsiyem:<\/p>\n<ul>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> &#8211; Biyoteknoloji hisseleri volatil olabilir; sizi uyutmayan bir pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ile ba\u015flay\u0131n<\/li>\n<li><strong>Uzun vadeye odaklan\u0131n<\/strong> &#8211; \u0130la\u00e7 geli\u015ftirme y\u0131llar al\u0131r; 3-5 y\u0131ll\u0131k perspektifle d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<li><strong>Uygun \u015fekilde \u00e7e\u015fitlendirin<\/strong> &#8211; T\u00fcm yat\u0131r\u0131mlar\u0131n\u0131z\u0131 tek bir biyoteknoloji sepetine koymay\u0131n<\/li>\n<li><strong>Stop-loss emirleri belirleyin<\/strong> &#8211; Beklenmedik d\u00fc\u015f\u00fc\u015flere kar\u015f\u0131 sermayenizi koruyun<\/li>\n<\/ul>\n<p>Ve mizahi yorumum: &#8220;APLS ticareti, t\u0131bbi ara\u015ft\u0131rmalar\u0131 izlemek gibidir &#8211; bazen klinik deneyler i\u00e7in g\u00fc\u00e7l\u00fc bir mide gerekir, ama ba\u015far\u0131l\u0131 tedaviler beklemeye de\u011fer k\u0131lar!&#8221;<\/p>\n<h2>Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option&#8217;\u0131n Avantajlar\u0131<\/h2>\n<p>Apellis Pharmaceuticals, Inc. (APLS) hisselerini nas\u0131l alaca\u011f\u0131n\u0131z\u0131 d\u00fc\u015f\u00fcnenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum depozito sadece 5 $<\/strong> &#8211; Stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> &#8211; Basit belge y\u00fckleme ile h\u0131zl\u0131ca i\u015flem yapmaya ba\u015flay\u0131n<\/li>\n<li><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong> &#8211; Karlar\u0131n\u0131za \u00e7e\u015fitli kolay y\u00f6ntemlerle eri\u015fin<\/li>\n<li><strong>Kullan\u0131c\u0131 dostu platform<\/strong> &#8211; Yeni ba\u015flayanlar i\u00e7in tasarlanm\u0131\u015f, geli\u015fmi\u015f \u00f6zellikler sunar<\/li>\n<\/ul>\n<h2>\u015eirket Genel Bak\u0131\u015f\u0131: 2025&#8217;te Apellis<\/h2>\n<p>Apellis Pharmaceuticals, tamamlay\u0131c\u0131 arac\u0131l\u0131 hastal\u0131k tedavisinde k\u00fcresel lider konumundad\u0131r. \u015eirket, klinik a\u015famadan ticari a\u015famaya ge\u00e7i\u015f yapm\u0131\u015f ve ciddi hastal\u0131klar\u0131 hedefleyen iki onayl\u0131 terapiye sahiptir.<\/p>\n<p>Amiral gemisi \u00fcr\u00fcn\u00fc SYFOVRE co\u011frafi atrofiyi tedavi ederken, EMPAVELI birden fazla nadir hastal\u0131\u011f\u0131 hedeflemektedir. 370 milyon $ nakit ve artan gelir ak\u0131\u015flar\u0131 ile Apellis hem bilimsel yenilik hem de i\u015f zekas\u0131 sergilemektedir.<\/p>\n<p><strong>\u0130lgin\u00e7 Ger\u00e7ek<\/strong>: 2025 y\u0131l\u0131nda Apellis biyoteknolojide nadir g\u00f6r\u00fclen bir ba\u015far\u0131ya imza att\u0131 &#8211; mevcut ilac\u0131 EMPAVELI&#8217;yi tamamen yeni durumlar\u0131 (C3G ve IC-MPGN) tedavi etmek i\u00e7in geni\u015fletti, b\u00f6ylece tamamen yeni bile\u015fikler geli\u015ftirmeden yeni gelir ak\u0131\u015flar\u0131 yaratt\u0131!<\/p>\n<p>Yat\u0131r\u0131m stratejileri ve piyasa analizleri hakk\u0131nda daha fazla e\u011fitim i\u00e7eri\u011fi i\u00e7in d\u00fczenli g\u00fcncellemeler ve i\u00e7g\u00f6r\u00fcler sunan <a href=\"\/blog\">Pocket Option blog<\/a> sayfam\u0131z\u0131 ziyaret edin.<\/p>\n"},"faq":[{"question":"Apellis Pharmaceuticals hisseleri nereden al\u0131n\u0131r?","answer":"Apellis Pharmaceuticals hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online i\u015flem platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"APLS hissesinin g\u00fcncel fiyat\u0131 nedir?","answer":"24 A\u011fustos 2025 itibar\u0131yla APLS hissesinin fiyat\u0131 yakla\u015f\u0131k 27,97 $ seviyesindedir."},{"question":"Apellis Pharmaceuticals hisselerine yat\u0131r\u0131m yapman\u0131n riskleri nelerdir?","answer":"Reg\u00fclasyon belirsizli\u011fi, artan rekabet, y\u00fcksek Ar-Ge maliyetleri ve piyasa volatilitesi ba\u015fl\u0131ca riskler aras\u0131ndad\u0131r."},{"question":"Apellis hisseleri i\u00e7in uzun vadeli beklentiler nelerdir?","answer":"Analistlere g\u00f6re 2025-2030 aras\u0131nda hisse fiyat\u0131nda \u00f6nemli b\u00fcy\u00fcme potansiyeli bulunmaktad\u0131r ve uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in al\u0131m \u00f6nerilmektedir."},{"question":"Apellis Pharmaceuticals hakk\u0131nda daha fazla bilgiye nereden ula\u015fabilirim?","answer":"\u015eirketin resmi web sitesi ve Pocket Option blog sayfas\u0131, yat\u0131r\u0131m stratejileri ve piyasa analizleri i\u00e7in faydal\u0131 kaynaklard\u0131r."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Apellis Pharmaceuticals hisseleri nereden al\u0131n\u0131r?","answer":"Apellis Pharmaceuticals hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online i\u015flem platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"APLS hissesinin g\u00fcncel fiyat\u0131 nedir?","answer":"24 A\u011fustos 2025 itibar\u0131yla APLS hissesinin fiyat\u0131 yakla\u015f\u0131k 27,97 $ seviyesindedir."},{"question":"Apellis Pharmaceuticals hisselerine yat\u0131r\u0131m yapman\u0131n riskleri nelerdir?","answer":"Reg\u00fclasyon belirsizli\u011fi, artan rekabet, y\u00fcksek Ar-Ge maliyetleri ve piyasa volatilitesi ba\u015fl\u0131ca riskler aras\u0131ndad\u0131r."},{"question":"Apellis hisseleri i\u00e7in uzun vadeli beklentiler nelerdir?","answer":"Analistlere g\u00f6re 2025-2030 aras\u0131nda hisse fiyat\u0131nda \u00f6nemli b\u00fcy\u00fcme potansiyeli bulunmaktad\u0131r ve uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in al\u0131m \u00f6nerilmektedir."},{"question":"Apellis Pharmaceuticals hakk\u0131nda daha fazla bilgiye nereden ula\u015fabilirim?","answer":"\u015eirketin resmi web sitesi ve Pocket Option blog sayfas\u0131, yat\u0131r\u0131m stratejileri ve piyasa analizleri i\u00e7in faydal\u0131 kaynaklard\u0131r."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Apellis Pharmaceuticals, Inc. (APLS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Apellis Pharmaceuticals, Inc. (APLS) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apellis Pharmaceuticals, Inc. (APLS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Apellis Pharmaceuticals, Inc. (APLS) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-24T06:27:16+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Apellis Pharmaceuticals, Inc. (APLS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Apellis Pharmaceuticals, Inc. (APLS) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-24T06:27:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\",\"name\":\"Apellis Pharmaceuticals, Inc. (APLS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Apellis Pharmaceuticals, Inc. (APLS) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"datePublished\":\"2025-08-24T06:27:16+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apellis Pharmaceuticals, Inc. (APLS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Apellis Pharmaceuticals, Inc. (APLS) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Apellis Pharmaceuticals, Inc. (APLS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Apellis Pharmaceuticals, Inc. (APLS) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/","og_locale":"tr_TR","og_type":"article","og_title":"Apellis Pharmaceuticals, Inc. (APLS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Apellis Pharmaceuticals, Inc. (APLS) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-24T06:27:16+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Apellis Pharmaceuticals, Inc. (APLS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Apellis Pharmaceuticals, Inc. (APLS) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-24T06:27:16+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/","name":"Apellis Pharmaceuticals, Inc. (APLS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Apellis Pharmaceuticals, Inc. (APLS) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","datePublished":"2025-08-24T06:27:16+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Apellis Pharmaceuticals, Inc. (APLS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Apellis Pharmaceuticals, Inc. (APLS) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":343831,"slug":"how-to-buy-apellis-pharmaceuticals","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"},"pt_AA":{"locale":"pt_AA","id":343827,"slug":"how-to-buy-apellis-pharmaceuticals","post_title":"Como comprar a\u00e7\u00f5es da Apellis Pharmaceuticals, Inc. (APLS) - Investimento em a\u00e7\u00f5es da Apellis Pharmaceuticals, Inc. (APLS)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/343830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=343830"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/343830\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334081"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=343830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=343830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=343830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}